Sagimet Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMT research report →
About the company
Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
- CEO
- David Happel
- IPO
- 2023
- Employees
- 16
- HQ
- San Mateo, CA, US
Price Chart
- Market Cap
- $247.95M
- P/E
- -5.64
- P/S
- 0.00
- P/B
- 2.42
- EV/EBITDA
- -4.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.57%
- ROIC
- -47.55%
- Revenue
- $0 · 0.00%
- Net Income
- $-51,038,000 · -12.01%
- EPS
- $-1.58 · -8.97%
- Op Income
- $-56,889,000
- FCF YoY
- -7.58%
- 52W High
- $11.41
- 52W Low
- $4.50
- 50D MA
- $7.15
- 200D MA
- $6.56
- Beta
- 3.38
- Avg Volume
- 1.81M
Get TickerSpark's AI analysis on SGMT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | SEIDENBERG BETH C | other | 39,567 |
| Jun 12, 26 | Hoelscher Paul W. | other | 39,567 |
| Jun 12, 26 | Jarrett Jennifer | other | 39,567 |
| Jun 12, 26 | GRAMMER ELIZABETH A | other | 39,567 |
| Jun 12, 26 | Kemble George | other | 39,567 |
| Jun 12, 26 | Phillips Anne M. | other | 39,567 |
| May 28, 26 | Chauche Thierry | other | 50,000 |
| May 28, 26 | Grauer Andreas | other | 35,000 |
| May 28, 26 | Rozek Elizabeth | other | 100,000 |
| May 28, 26 | Happel David | other | 300,000 |
Our SGMT coverage
Recent articles, reports, and earnings notes.
No research on SGMT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGMT report →Similar companies
Peers in the same neighborhood.